喜讯丨XTL6001中选2026美国糖尿病协会科学年会(ADA) 减重与肾病两大适应症研究成果同时亮相
MICOT
点击蓝字 关注我们
Slide to view different languages
滑动查看不同语言
XTL6001中选2026美国糖尿病协会科学年会(ADA)
减重与肾病两大适应症研究成果同时亮相
近日，陕西麦科奥特医药科技股份有限公司自主研发的全球首创三靶点长效蛋白药物XTL6001的研究成果成功中选 2026 年美国糖尿病协会（ADA）科学年会，将以两项壁报（poster）形式，分别展示其在减重及慢性肾病领域的研究成果。
美国糖尿病协会（ADA）科学年会是全球糖尿病与代谢性疾病领域规模最大、影响力最深远的学术盛会，汇聚了全球顶尖的领域专家与研究团队。此次中选，标志着麦科奥特在代谢性疾病创新药研发领域的实力获得国际权威认可，也让这款多靶点创新药登上全球糖尿病及代谢病领域的顶级学术平台。
XTL6001
作为全球首创的三靶点长效蛋白药物，XTL6001 依托靶点协同作用，集体重管理、脂代谢改善、蛋白尿降低等多重获益于一体，为代谢综合征提供综合解决方案，一站式应对代谢紊乱所致多器官损伤，直击未被满足的临床需求。双壁报同步入选，充分印证了该药物的研发价值与临床潜力。
此次中选的两份摘要分别为：
01
XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Weight Loss and Obesity-Related Complications
XTL6001 在等效剂量下减重效果优于司美格鲁肽，停药后体重反弹极小，且不影响进食量，提示长期安全性与耐受性更优；同时，在减少内脏脂肪、提升肌肉占比方面同样优于司美格鲁肽，并能改善血脂及肝脏脂质代谢。
02
XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Chronic Kidney Disease/Diabetic Kidney Disease with Proteinuria and Hyperuricemia
XTL6001 在 3 种大鼠肾病模型中，可剂量依赖性降低24小时尿白蛋白、改善肾功能，延缓肾病进展，尿白蛋白降幅显著优于非奈利酮及非奈利酮联合度拉糖肽方案，同时可降低血肌酐、尿素氮与尿酸水平，改善肾功能不全。
根据会议要求，这两份海报将在整个会议期间（6月5日傍晚至6月8日）于 Poster Hall 展示。麦科奥特将于当地时间6月8日（周一）中午12:30-1:30的 General Poster Sessions 时段在现场答疑，与全球顶尖学者进行深入交流。
I期临床顺利推进，剑指千亿市场
目前，XTL6001注射液已完成在健康受试者及肥胖受试者中进行的I期临床试验，进行了药物安全性、耐受性、药代动力学及初步的疗效评估。全球减重及代谢类药物市场持续扩容，预计2030年将达到1300亿美元。XTL6001凭借其独特的“减重减脂、降蛋白尿、多靶器官保护”三位一体的差异化优势，有望在未来激烈的市场竞争中占据重要一席。
关于XTL6001的更多研究数据，敬请关注2026年ADA年会期间的详细壁报展示。
MICOT
欢迎关注
麦科奥特｜MICOT
XTL6001 Selected for the 2026 American Diabetes Association (ADA) Scientific Sessions, with Dual Posters in Weight Management and Kidney Disease
Recently, research findings on XTL6001, a globally first-in-class triple-target long-acting protein therapeutic developed by Shaanxi Micot Pharmaceutical Technology Co., Ltd., were selected for presentation at the 2026 American Diabetes Association Scientific Sessions. Two posters will present its results in weight management and chronic kidney disease, respectively.
The ADA Scientific Sessions are the largest and most influential global conference in diabetes and metabolic diseases, bringing together leading experts and research teams. This acceptance signifies international recognition of Micot’s capabilities in innovative metabolic drug development and places this multi-target novel therapeutic on a premier global academic platform.
XTL6001
As a globally first-in-class triple-target long-acting protein therapeutic, XTL6001 leverages synergistic target activity to deliver multiple benefits, including weight reduction, improved lipid metabolism, and reduced proteinuria. It provides a comprehensive solution for metabolic syndrome, addressing multi-organ damage from metabolic dysregulation in a one-stop approach and addressing unmet clinical needs. Selection of both posters further supports its development value and clinical potential.
The two accepted abstracts are as follows:
01
XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Weight Loss and Obesity-Related Complications
XTL6001 outperforms Semaglutide in weight reduction at equivalent dose with minimal weight rebound after treatment cessation and without substantial impact on food intake suggesting favorable long-term safety and tolerability. Furthermore, XTL6001 outperforms Semaglutide in decrease in visceral fat weight, in increase the proportion of muscle mass and decrease proportion of fat mass, thereby reverse muscle-to-fat ratio. XTL6001 improves blood and hepatic lipid metabolism.
02
XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Chronic Kidney Disease/Diabetic Kidney Disease with Proteinuria and Hyperuricemia
In all 3 rat models, XTL6001 dose-dependently reduced 24h urinary albumin, improved renal function and GFR, thereby delaying kidney disease progression. The reduction in 24h urinary albumin was significantly superior to that of Finerenone alone or Finerenone combined with Dulaglutide. XTL6001 also significantly reduced blood creatinine, blood urea nitrogen, and uric acid levels, improving renal insufficiency.
Per conference requirements, both posters will be displayed in the Poster Hall throughout the meeting (evening of June 5 to June 8). Micot will host an on-site Q&A during the General Poster Sessions from 12:30–13:30 (local time) on Monday, June 8, engaging with global experts.
Phase I Clinical Trial Progressing Smoothly, Targeting a Hundred-Billion-Dollar Market
XTL6001 injection has completed Phase I trials in healthy subjects and individuals with obesity, evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy. The global market for weight management and metabolic therapeutics continues to expand and is projected to reach USD 130 billion by 2030. With its differentiated “weight/fat reduction, proteinuria reduction, and multi-organ protection” profile, XTL6001 is well positioned to secure a significant market share.
For more detailed data on XTL6001, please stay tuned to the full poster presentations during the 2026 ADA Scientific Sessions.
MICOT
欢迎关注
麦科奥特｜MICOT
详情
奋斗为本、求是创新、协作共赢
